Skip to content

Charles River Laboratories Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 4, 2026 results vs estimates

Charles River Laboratories · E.CRL.NYSE · United States
Use symbol E.CRL.NYSE in our API & Excel add-in to retrieve this data ↓
376.10
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 48.41%

Charles River Laboratories Forecast

Charles River Laboratories short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 48.4% a year, a typical one-standard-deviation range is 350.46–401.74 over a week, 323.55–428.65 over a month and 194.05–558.15 over a year. (Signals as of 1 Nov 2026.)

Charles River Laboratories Price Chart

MacroFinance.ai

Charles River Laboratories Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Charles River Laboratories
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Charles River Laboratories
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Charles River Laboratories
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Charles River Laboratories
P/E
454.69x
Stretched vs own history
QoQ —
YoY —
now 454.6854380 low454.69 high
ⓘP/E As of 22 Nov 2026.See Charles River Laboratories returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Charles River Laboratories
P/S
4.59x
Stretched vs own history
QoQ +28.4%
YoY +123.1%
now 4.59471.83 low4.59 high
ⓘP/S As of 22 Nov 2026.See Charles River Laboratories returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Charles River Laboratories
P/B
5.66x
Stretched vs own history
QoQ +12.3%
YoY +132.7%
now 5.66232.34 low6.14 high
ⓘP/B As of 22 Nov 2026.See Charles River Laboratories returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Charles River Laboratories
EV/EBITDA
71.36x
Stretched vs own history
QoQ −8.3%
YoY +244.1%
now 71.356520.14 low91.9 high
ⓘEV/EBITDA As of 22 Nov 2026.See Charles River Laboratories returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Charles River Laboratories
EV/Sales
5.26x
Stretched vs own history
QoQ +22.7%
YoY +97.7%
now 5.26062.54 low5.26 high
ⓘEV/Sales As of 22 Nov 2026.See Charles River Laboratories returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Charles River Laboratories
FCF Yield
2.2%
Weak vs own history
QoQ −15.5%
YoY −66.7%
now 2.18712.13 low6.86 high
ⓘFCF Yield As of 22 Nov 2026.See Charles River Laboratories returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Charles River Laboratories
Earnings Yield
0.2%
Mid-range vs own history
QoQ −113.2%
YoY −121.8%
now 0.2199-2.5 low0.26 high
ⓘEarnings Yield As of 22 Nov 2026.See Charles River Laboratories returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Charles River Laboratories
Market Cap
$18.3B
Highest in 5 years
QoQ +27.7%
YoY +120.5%
now 18272.44247,384 low18,272 high
ⓘMarket Cap As of 22 Nov 2026.See Charles River Laboratories returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Charles River Laboratories
Net Debt
$2.6B
Mid-range vs own history
QoQ −6.6%
YoY +9.3%
now 2648.4312,424 low2,864 high
ⓘNet Debt As of 22 Nov 2026.See Charles River Laboratories returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Charles River Laboratories
Net Debt / EBITDA
9.03x
High vs own history
QoQ −29.8%
YoY +92.5%
now 9.03324.69 low12.86 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Charles River Laboratories returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Charles River Laboratories
Current Ratio
1.41x
Mid-range vs own history
QoQ +4.6%
YoY +3.2%
now 1.40921.29 low1.41 high
ⓘCurrent Ratio As of 22 Nov 2026.See Charles River Laboratories returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Charles River Laboratories
Quick Ratio
1.12x
Mid-range vs own history
QoQ +7.0%
YoY +1.8%
now 1.11581.02 low1.12 high
ⓘQuick Ratio As of 22 Nov 2026.See Charles River Laboratories returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Charles River Laboratories
Interest Coverage
0.08x
Weak vs own history
QoQ −110.3%
YoY −90.6%
now 0.0751-0.73 low0.8 high
ⓘInterest Coverage As of 22 Nov 2026.See Charles River Laboratories returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Charles River Laboratories
Debt / Equity
0.88x
Mid-range vs own history
QoQ −17.2%
YoY +14.3%
now 0.88280.77 low1.07 high
ⓘDebt / Equity As of 22 Nov 2026.See Charles River Laboratories returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Charles River Laboratories
Piotroski F-Score
8
Strong vs own history
QoQ +100.0%
YoY +166.7%
now 83 low8 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Charles River Laboratories returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Charles River Laboratories
Altman Z-Score
3.55
Strong vs own history
QoQ +34.3%
YoY +59.7%
now 3.55471.74 low3.55 high
ⓘAltman Z-Score As of 22 Nov 2026.See Charles River Laboratories returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Charles River Laboratories, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Charles River Laboratories fundamentals: income statement, balance sheet & cash flow

Charles River Laboratories reported revenue of $4.02bn and net income of -$144.3m in FY2025, the year ended 31 December 2025 — revenue down 0.9% and net income down 1,501.7% on the prior year. Free cash flow was $518.5m. These figures are as reported in the filings, not restated: 28 fiscal years and 107 quarters of history, back to December 1998. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$4.02bn
-0.9%
Net income
-$144.3m
-1,501.7%
Gross margin
30.52%
Free cash flow
$518.5m
+3.4%
Net debt
$2.85bn
Shares short (30 Oct 2026)
2.99m
2.23 days to cover
Charles River Laboratories income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue4,015.44,050.04,129.43,976.13,540.2
Cost of revenue2,789.82,718.22,626.92,513.42,205.5
Gross profit1,225.61,331.81,502.61,462.71,334.6
Selling, general & admin.723.4751.0750.4665.1619.9
Operating income507.8227.3617.3651.0589.9
EBITDA410.8581.11,032.1986.1820.2
Interest expense107.0126.3136.759.373.9
Pre-tax income-99.593.1581.3623.0480.7
Income tax42.767.8100.9130.481.9
Net income-144.310.3474.6486.2391.0

Download Charles River Laboratories fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.CRL.NYSE&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 28 fiscal years and 107 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Charles River Laboratories

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Charles River Laboratories Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Charles River Laboratories; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Charles River Laboratories’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Charles River Laboratories behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Charles River Laboratories (United States)

Charles River Laboratories is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Charles River Laboratories

Frequently asked questions

What is Charles River Laboratories?
Charles River Laboratories is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Charles River Laboratories price?
The latest close is 376.1 (1 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Charles River Laboratories in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Charles River Laboratories?
20-day realised volatility is 48.4% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 14.0% over a month and 6.8% over a week.
What factors affect Charles River Laboratories?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Charles River Laboratories, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Charles River Laboratories?
58 backtested tactical asset allocation strategies trade Charles River Laboratories through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Charles River Laboratories returns analysed?
The Statistical Distribution of Returns section shows the distribution of Charles River Laboratories daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Charles River Laboratories historical data?
In the Free historical data section of this page: the last 10 years of Charles River Laboratories daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Charles River Laboratories historical data (last 10 years)

Browse or instantly download the last 10 years of Charles River Laboratories daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.CRL.NYSE&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20314.32
2026-11-19327.93
2026-11-18333.25
2026-11-17332.16
2026-11-16335.52
2026-11-13337.97
2026-11-12340.81
2026-11-11342.69
2026-11-10345.8
2026-11-09353.34
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.